止血剤の世界市場：タイプ別、製剤別、用途別、エンドユーザー別、流通チャネル別、地域別 - 市場規模、産業力学、機会分析、予測（2025年～2033年）

止血剤市場は、世界中の外科手術のペースと密接に結びついており、拡大する手技における効果的な出血コントロールに対する需要の高まりを反映しています。2024年の市場規模は約28億8,413万米ドルで、今後も安定的に成長し、2033年までに48億3,968万米ドルに達すると予測されます。この成長は、2025年～2033年のCAGRにして5.92%です。この拡大の主な促進要因の1つは、腹腔鏡手術やロボット手術などの低侵襲手術技法の採用の増加です。

地域別では、北米が確立された医療インフラと高い手術件数の恩恵を受けて、止血剤の消費で引き続き市場を独占しています。しかし、アジア太平洋は、特に中国やインドのような人口の多い国々における、政府出資の外傷ネットワークへの多額の投資や腹腔鏡手術の急増に後押しされ、急速に地歩を固めつつあります。この成長は、アジア太平洋における外科手術の増加や医療アクセスの拡大を利用しようとする止血剤メーカーにとっての重要な成長エンジンとして浮上し、市場力学の変化を示唆しています。

注目すべき市場の発展

止血剤市場は、Johnson & Johnson、Baxter International、Pfizer Inc.、B. Braun SE、Becton, Dickinson and Company（BD）などの主要企業が牽引しています。これらの産業大手は強力な世界的フットプリントを誇り、精力的な研究開発、戦略的提携、継続的な製品革新を通じて市場地位の向上に深くコミットし続けています。

Baxter Internationalは、次世代止血ソリューションの開発に専念する50人の科学者チームを擁する自社のApplied Hemostasis laboratoryで、このイノベーション主導のアプローチを体現しています。2023年だけでも、この研究所は42の特許ファミリーを出願し、せん断減粘性ゼラチンや凍結保護トロンビン複合薬などの先進材料に注力しています。これらのイノベーションは、止血剤の有効性と用途の多様性を向上させ、最新の外科手術の微妙なニーズに対応することを目的としています。

一方、BDは買収を通じて戦略的にポートフォリオを拡大しており、Tissuemedの2億1,400万米ドルでの買収がその例です。この買収により、BDはTissuemedの超薄型ポリエチレングリコールパッチ技術を利用できるようになり、製品の幅が広がり、より専門的で効果的な止血剤の選択肢を市場に提供できるようになっています。このような動きは、革新的な製品への的を絞った投資を通じてその地位を強化するというBDのコミットメントを示しています。

主な成長促進要因

低侵襲手術（MIS）件数の急増が、止血剤市場の拡大を後押しするもっとも強力な要因として際立っています。International Society for Minimally Invasive Surgeryによると、2024年に世界で約1億800万件の腹腔鏡手術、ロボット手術、内視鏡手術が実施される見込みです。これは2022年と比較して約1,100万件の増加であり、幅広い外科でMIS技術の採用が加速していることを物語っています。

止血剤は現在、低侵襲手術のおよそ3件に1件の割合で使用されており、2024年だけで約3,600万組が使用されることになります。この広範な統合は、止血剤が安全で効率的なMIS手術を可能にする上で重要な役割を果たしていることを強調しています。低侵襲技法の継続的な拡大により、止血剤製品に対する旺盛な需要が維持され、市場内の技術革新と成長がさらに促進されると予測されます。

新たな機会の動向

コラーゲンとキトサンのハイブリッド止血剤に対する科学的関心はますます高まっており、この動向が止血剤市場の競合力学を大きく変えつつあります。これらのハイブリッド製剤は、コラーゲンの有益な特性とキトサンのユニークな特性を組み合わせ、止血性能の向上と組織適合性の向上をもたらします。2023年1月～2024年3月、European Database on Medical Devices（EUDAMED）はコラーゲン・キトサン複合製品について11件の新規CEマーク承認を記録しており、同期間に酸化セルロースベースの止血剤がわずか3件承認されたのとは対照的です。

当レポートでは、世界の止血剤市場について調査分析し、各セグメントの市場規模と予測、市場力学と動向、企業プロファイルなどを提供しています。

目次

第1章 調査の枠組み

• 調査目的
• 製品の概要
• 市場のセグメンテーション

第2章 調査手法

第3章 エグゼクティブサマリー：世界の止血剤市場

第4章 世界の止血剤市場の概要

• 産業バリューチェーン分析
  • 材料プロバイダー
  • メーカー
  • 卸売業者
  • エンドユーザー
• 産業の見通し
  • 天然由来の局所・外用止血バイオ材料
  • 合成由来の局所・外用止血バイオ材料
• PESTLE分析
• ポーターのファイブフォース分析
• 市場力学と動向
  • 成長促進要因
  • 課題
  • 主要動向
• 市場成長動向に対するCOVID-19の影響の評価
• 市場の成長と見通し
  • 市場の収益の推計と予測（2020年～2033年）
  • 市場規模の推計と予測（2020年～2033年）
• 競合ダッシュボード
  • 市場集中率
  • 企業の市場シェア分析（金額）（2024年）
  • 競合マッピング

第5章 世界の止血剤市場の分析：タイプ別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • 局所止血剤
  • その他

第6章 世界の止血剤市場の分析：製剤別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • シート・パッド止血剤
  • スポンジ止血剤
  • 粉末止血剤
  • マトリクス・ゲル止血剤
  • その他

第7章 世界の止血剤市場の分析：用途別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • 整形外科手術
  • 一般外科手術
  • 神経外科手術
  • 心血管手術
  • 再建手術
  • 婦人科手術
  • その他

第8章 世界の止血剤市場の分析：エンドユーザー別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • 病院
  • 外来手術センター
  • 在宅ケア
  • その他

第9章 世界の止血剤市場の分析：流通チャネル別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • オンライン
  • オフライン

第10章 世界の止血剤市場の分析：地域別

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • 北米
  • 欧州
  • アジア太平洋
  • 中東・アフリカ
  • 南米

第11章 北米の止血剤市場の分析

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • タイプ別
  • 製剤別
  • 用途別
  • エンドユーザー別
  • 流通チャネル別
  • 国別

第12章 欧州の止血剤市場の分析

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • タイプ別
  • 製剤別
  • 用途別
  • エンドユーザー別
  • 流通チャネル別
  • 国別

第13章 アジア太平洋の止血剤市場の分析

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • タイプ別
  • 製剤別
  • 用途別
  • エンドユーザー別
  • 流通チャネル別
  • 国別

第14章 中東・アフリカの止血剤市場の分析

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • タイプ別
  • 製剤別
  • 用途別
  • エンドユーザー別
  • 流通チャネル別
  • 国別

第15章 南米の止血剤市場の分析

• 重要な知見
• 市場規模と予測（2020年～2033年）
  • タイプ別
  • 製剤別
  • 用途別
  • エンドユーザー別
  • 流通チャネル別
  • 国別

第16章 企業プロファイル

• B.Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Co.
• Gelita Medical GmbH
• Hemostatis LLC
• Integra Life Sciences Holding Corp.
• Johnson and Johnson
• Medtronic PLC
• Pfizer Inc.
• Stryker Corp.
• Teleflex Inc.
• その他の著名な企業

The hemostats market is closely tied to the pace of surgical activity worldwide, reflecting the growing demand for effective bleeding control in an expanding range of procedures. In 2024, the market is valued at approximately US$ 2,884.13 million and is forecasted to grow steadily, reaching an estimated valuation of US$ 4,839.68 million by 2033. This growth corresponds to a compound annual growth rate (CAGR) of 5.92% between 2025 and 2033. One of the key drivers behind this expansion is the increasing adoption of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries.

Regionally, North America continues to dominate the hemostats market in terms of procedural consumption, benefiting from a well-established healthcare infrastructure and high surgical volumes. However, the Asia-Pacific region is rapidly gaining ground, propelled by significant investments in government-funded trauma networks and a surge in laparoscopic surgeries, especially in populous countries like China and India. This growth signals a shift in market dynamics as Asia-Pacific emerges as a vital growth engine for hemostatic product manufacturers seeking to capitalize on increasing surgical activities and expanding healthcare access in the region.

Noteworthy Market Developments

The hemostats market is led by several prominent companies, including Johnson & Johnson, Baxter International, Pfizer Inc., B. Braun SE, and Becton, Dickinson and Company (BD). These industry giants boast a strong global footprint and remain deeply committed to advancing their market positions through vigorous research and development efforts, strategic partnerships, and continuous product innovation.

Baxter International exemplifies this innovation-driven approach with its Applied Hemostasis laboratory, staffed by a team of 50 scientists dedicated to developing next-generation hemostatic solutions. In 2023 alone, this lab filed 42 patent families, focusing on advanced materials such as shear-thinning gelatin and lyoprotected thrombin combinations. These innovations aim to improve the efficacy and application versatility of hemostats, addressing the nuanced needs of modern surgical procedures.

Meanwhile, BD has strategically expanded its portfolio through acquisitions, exemplified by its purchase of Tissuemed for $214 million. This acquisition granted BD access to Tissuemed's ultra-thin polyethylene glycol patch technology, enhancing its product breadth and enabling it to offer more specialized and effective hemostatic options to the market. Such moves demonstrate BD's commitment to strengthening its position through targeted investments in innovative products.

Core Growth Drivers

The rapid growth in minimally invasive surgery (MIS) volumes stands out as the most powerful driver fueling expansion in the hemostats market. According to the International Society for Minimally Invasive Surgery, approximately 108 million laparoscopic, robotic, and endoscopic procedures are expected to be performed globally in 2024. This represents an increase of about 11 million cases compared to 2022, highlighting the accelerating adoption of MIS techniques across a wide range of surgical specialties.

Hemostatic agents are now deployed in roughly one out of every three minimally invasive surgeries, translating to nearly 36 million units utilized in 2024 alone. This widespread integration underscores the vital role hemostats play in enabling safe and efficient MIS procedures. The continued expansion of minimally invasive techniques is expected to sustain strong demand for hemostatic products, further driving innovation and growth within the market

Emerging Opportunity Trends

Scientific interest is increasingly shifting toward hybrid collagen-chitosan hemostats, a trend that is significantly reshaping the competitive dynamics within the hemostats market. These hybrid formulations combine the beneficial properties of collagen with the unique features of chitosan, offering enhanced hemostatic performance and improved tissue compatibility. Between January 2023 and March 2024, the European Database on Medical Devices (EUDAMED) recorded 11 new CE Mark approvals for collagen-chitosan composite products, a stark contrast to the mere three approvals granted for oxidized cellulose-based hemostats during the same period.

In the United States, the Food and Drug Administration (FDA) cleared six collagen-chitosan hybrid hemostats within the same timeframe. Notably, half of these products received Breakthrough Device designation, underscoring their innovative nature and clinical promise. These designations were largely based on rapid clot formation benchmarks demonstrated through preclinical testing, where bleeding times were reduced to under 20 seconds in porcine liver models.

Barriers to Optimization

Rising raw-material prices are significantly impacting profitability within the bovine-collagen-based biosurgicals segment, posing a substantial challenge to the hemostats market in 2024. According to data from the U.S. Department of Agriculture, the cost of medical-grade bovine tendon collagen surged to $19.40 per kilogram in April 2024, up sharply from $13.00 per kilogram in 2022. Although the amount of purified collagen used in each absorbable patch averages just 1.9 grams, this increase translates to a material cost of approximately $0.037 per unit.

Baxter's most recent 10-K filing highlights the financial strain caused by these raw material price hikes, reporting a $94 million year-over-year increase in biomaterial expenditures, driven predominantly by rising bovine collagen costs. This surge has compressed gross margins by roughly $6 per device, a notable figure that directly affects profitability. To counterbalance these increased costs, manufacturers have implemented price adjustments at the SKU level, with hospital group purchasing organization (GPO) catalogs reflecting average price hikes of around $9 per unit.

Detailed Market Segmentation

By Type, the topical category occupies a dominant position in the hemostats market, commanding over 85.46% of the total market share. This prominence is largely attributed to the versatility and convenience that topical hemostatic agents offer across a broad spectrum of surgical workflows. Unlike some hemostatic products that require specialized equipment or ancillary hardware, topical agents can be applied directly to the bleeding site with minimal preparation, making them highly compatible with both open surgeries and minimally invasive procedures.

By formulation, matrices and gels dominate the hemostats market in terms of formulation revenue, accounting for 34.26% of the total market share. Their popularity stems from their unique ability to combine the ease of handling typically associated with topical agents with the flexibility and adaptability of liquids. This hybrid quality makes them particularly well-suited for controlling bleeding in complex surgical fields where blood loss often originates from irregular cavities or delicate, friable parenchymal tissue.

Based on application, orthopedic surgery represents a significant segment of the hemostats market, capturing more than 30.26% of the total market share based on application. This prominence is largely due to the nature of orthopedic procedures, which tend to generate some of the heaviest routine blood loss among elective surgical specialties. As a result, orthopedic theaters are among the most intensive users of hemostatic products, relying heavily on these adjuncts to manage bleeding effectively during complex joint, spine, and trauma fixation surgeries.

By End Users, hospitals hold a commanding position in the hemostats market, capturing over 56.20% of the total market share. This dominance is primarily due to their responsibility for managing the highest acuity cases, which require a broad range of surgical consumables, including hemostatic products. Hospitals also exercise significant control over procurement formularies, enabling them to standardize and streamline the acquisition of essential items to meet the demands of complex surgical procedures.

Segment Breakdown

By Type

• Topical Hemostats
  • Mechanical Hemostats
    • ORC Based
    • Gelatin Based
    • Collagen Based
• Polysaccharide Based Topical Hemostats
  • Active Hemostats
  • Flowable Hemostats
• Topical Thrombin Based Topical Hemostats
• Others

By Formulation

• Sheet and Pad Hemostats
• Sponge Hemostats
• Powder Hemostats
• Matrix and Gel Hemostats
• Others

By Application

• Orthopedic Surgery
• General Surgery
• Neurological Surgery
• Cardiovascular Surgery
• Reconstructive Surgery
• Gynecological Surgery
• Others

By End User

• Hospitals
• Ambulatory Surgical Centers
• Home Care
• Others

By Distribution Channel

• Online
• Offline
  • Direct
  • Distributor

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Western Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Western Europe
  • Eastern Europe
    • Poland
    • Russia
    • Rest of Eastern Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
• South America
  • Argentina
  • Brazil
  • Rest of South America

Leading Market Participants

• B.Braun Melsungen AG
• Baxter International Inc.
• Becton Dickinson and Co.
• Gelita Medical GmbH
• Hemostatis LLC
• Integra Life Sciences Holding Corp.
• Johnson and Johnson
• Medtronic PLC
• Pfizer Inc.
• Stryker Corp.
• Teleflex Inc.
• Other Prominent Players

Table of Content

Chapter 1. Research Framework

• 1.1. Research Objective
• 1.2. Product Overview
• 1.3. Market Segmentation

Chapter 2. Research Methodology

• 2.1. Qualitative Research
  • 2.1.1. Primary & Secondary Sources
• 2.2. Quantitative Research
  • 2.2.1. Primary & Secondary Sources
• 2.3. Breakdown of Primary Research Respondents, By Region
• 2.4. Assumption for the Study
• 2.5. Market Size Estimation
• 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Hemostats Market

Chapter 4. Global Hemostats Market Overview

• 4.1. Industry Value Chain Analysis
  • 4.1.1. Material Provider
  • 4.1.2. Manufacturer
  • 4.1.3. Distributor
  • 4.1.4. End User
• 4.2. Industry Outlook
  • 4.2.1. Topical and Externally Administered Hemostatic Biomaterials from Natural Sources
  • 4.2.2. Topical and Externally Administered Hemostatic Biomaterials from Synthetic Sources
• 4.3. PESTLE Analysis
• 4.4. Porter's Five Forces Analysis
  • 4.4.1. Bargaining Power of Suppliers
  • 4.4.2. Bargaining Power of Buyers
  • 4.4.3. Threat of Substitutes
  • 4.4.4. Threat of New Entrants
  • 4.4.5. Degree of Competition
• 4.5. Market Dynamics and Trends
  • 4.5.1. Growth Drivers
  • 4.5.2. Challenges
  • 4.5.3. Key Trends
• 4.6. Covid-19 Impact Assessment on Market Growth Trend
• 4.7. Market Growth and Outlook
  • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
  • 4.7.2. Market Volume Estimates and Forecast (000' Units), 2020 - 2033
• 4.8. Competition Dashboard
  • 4.8.1. Market Concentration Rate
  • 4.8.2. Company Market Share Analysis (Value %), 2024
  • 4.8.3. Competitor Mapping

Chapter 5. Global Hemostats Market Analysis, By Type

• 5.1. Key Insights
• 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 5.2.1. Topical Hemostats
    • 5.2.1.1. Mechanical Hemostats
      • 5.2.1.1.1. ORC Based
      • 5.2.1.1.2. Gelatin Based
      • 5.2.1.1.3. Collagen Based
    • 5.2.1.2. Polysaccharide Based Topical Hemostats
      • 5.2.1.2.1. Active Hemostats
      • 5.2.1.2.2. Flowable Hemostats
    • 5.2.1.3. Topical Thrombin Based Topical Hemostats
  • 5.2.2. Others

Chapter 6. Global Hemostats Market Analysis, By Formulation

• 6.1. Key Insights
• 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 6.2.1. Sheet and Pad Hemostats
  • 6.2.2. Sponge Hemostats
  • 6.2.3. Powder Hemostats
  • 6.2.4. Matrix and Gel Hemostats
  • 6.2.5. Others

Chapter 7. Global Hemostats Market Analysis, By Application

• 7.1. Key Insights
• 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 7.2.1. Orthopedic Surgery
  • 7.2.2. General Surgery
  • 7.2.3. Neurological Surgery
  • 7.2.4. Cardiovascular Surgery
  • 7.2.5. Reconstructive Surgery
  • 7.2.6. Gynecological Surgery
  • 7.2.7. Others

Chapter 8. Global Hemostats Market Analysis, By End User

• 8.1. Key Insights
• 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 8.2.1. Hospitals
  • 8.2.2. Ambulatory Surgical Centers
  • 8.2.3. Home Care
  • 8.2.4. Others

Chapter 9. Global Hemostats Market Analysis, By Distribution Channel

• 9.1. Key Insights
• 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 9.2.1. Online
  • 9.2.2. Offline
    • 9.2.2.1. Direct
    • 9.2.2.2. Distributor

Chapter 10. Global Hemostats Market Analysis, By Region

• 10.1. Key Insights
• 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 10.2.1. North America
    • 10.2.1.1. The U.S.
    • 10.2.1.2. Canada
    • 10.2.1.3. Mexico
  • 10.2.2. Europe
    • 10.2.2.1. Western Europe
      • 10.2.2.1.1. The UK
      • 10.2.2.1.2. Germany
      • 10.2.2.1.3. France
      • 10.2.2.1.4. Italy
      • 10.2.2.1.5. Spain
      • 10.2.2.1.6. Rest of Western Europe
    • 10.2.2.2. Eastern Europe
      • 10.2.2.2.1. Poland
      • 10.2.2.2.2. Russia
      • 10.2.2.2.3. Rest of Eastern Europe
  • 10.2.3. Asia Pacific
    • 10.2.3.1. China
    • 10.2.3.2. India
    • 10.2.3.3. Japan
    • 10.2.3.4. South Korea
    • 10.2.3.5. Australia & New Zealand
    • 10.2.3.6. ASEAN
    • 10.2.3.7. Rest of Asia Pacific
  • 10.2.4. Middle East & Africa
    • 10.2.4.1. UAE
    • 10.2.4.2. Saudi Arabia
    • 10.2.4.3. South Africa
    • 10.2.4.4. Rest of MEA
  • 10.2.5. South America
    • 10.2.5.1. Argentina
    • 10.2.5.2. Brazil
    • 10.2.5.3. Rest of South America

Chapter 11. North America Hemostats Market Analysis

• 11.1. Key Insights
• 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 11.2.1. By Type
  • 11.2.2. By Formulation
  • 11.2.3. By Application
  • 11.2.4. By End User
  • 11.2.5. By Distribution Channel
  • 11.2.6. By Country

Chapter 12. Europe Hemostats Market Analysis

• 12.1. Key Insights
• 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 12.2.1. By Type
  • 12.2.2. By Formulation
  • 12.2.3. By Application
  • 12.2.4. By End User
  • 12.2.5. By Distribution Channel
  • 12.2.6. By Country

Chapter 13. Asia Pacific Hemostats Market Analysis

• 13.1. Key Insights
• 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 13.2.1. By Type
  • 13.2.2. By Formulation
  • 13.2.3. By Application
  • 13.2.4. By End User
  • 13.2.5. By Distribution Channel
  • 13.2.6. By Country

Chapter 14. Middle East and Africa Hemostats Market Analysis

• 14.1. Key Insights
• 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 14.2.1. By Type
  • 14.2.2. By Formulation
  • 14.2.3. By Application
  • 14.2.4. By End User
  • 14.2.5. By Distribution Channel
  • 14.2.6. By Country

Chapter 15. South America Hemostats Market Analysis

• 15.1. Key Insights
• 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn & 000' Units)
  • 15.2.1. By Type
  • 15.2.2. By Formulation
  • 15.2.3. By Application
  • 15.2.4. By End User
  • 15.2.5. By Distribution Channel
  • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

• 16.1. B.Braun Melsungen AG
• 16.2. Baxter International Inc.
• 16.3. Becton Dickinson and Co.
• 16.4. Gelita Medical GmbH
• 16.5. Hemostatis LLC
• 16.6. Integra Life Sciences Holding Corp.
• 16.7. Johnson and Johnson
• 16.8. Medtronic PLC
• 16.9. Pfizer Inc.
• 16.10. Stryker Corp.
• 16.11. Teleflex Inc.
• 16.12. Other Prominent Players